FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386755083> ?p ?o ?g. }

• W4386755083 endingPage "29" @default.
• W4386755083 startingPage "18" @default.
• W4386755083 abstract "This continuing medical education-accredited symposium, held at the 2023 International Society for Thrombosis and Haemostasis (ISTH) congress in Montréal, Canada, focused on current unmet needs in anticoagulation, especially in the atrial fibrillation (AF) population, and reflected on the promise of the emerging class of Factor XI inhibitors for stroke prevention (SPAF) in susceptible patients. The faculty agreed that, although direct oral anticoagulants (DOAC) have represented a major advance compared with vitamin K antagonists, their utilisation remains suboptimal, often due to the prevailing fear of bleeding in many types of patients. Older age alone can be a reason for withholding anticoagulation, due to the risk and implications of bleeding. Frailty and comorbidities, such as chronic kidney disease (CKD), which can adversely affect the bioavailability of DOACs, are also deterrents to optimal anticoagulant use. Clinicians may try to avoid or mitigate bleeding by inappropriately prescribing low doses of DOACs, an off-label practice that has been found to fail to protect patients from thrombotic risk, without attenuating the risk of bleeding. In addition, the potential for drug-drug interactions and poor adherence also limit the optimal use of DOACs in real-world clinical practice. A recent patient survey focusing on the topic of ‘minor bleeding’, often referred to by clinicians as ‘nuisance bleeding’, and typically not well captured in clinical trials, revealed the far-reaching impact of ongoing problems with bleeding on quality of life, and the possibility that these experiences may deter patients from adherence to their prescribed anticoagulant regimen. Factor XI represents a promising new target for anticoagulation, which may minimise the risk of bleeding by pharmacologically ‘uncoupling’ the clotting pathway, leading to pathological thrombosis from the cascade largely responsible for physiological haemostasis. Phase II research with investigational Factor XI inhibitors has established their antithrombotic and safety potential, and some of these agents may also avoid other practical drawbacks of DOACs. Phase III evaluation of Factor XI inhibition is ongoing in a number of clinical settings." @default.
• W4386755083 created "2023-09-15" @default.
• W4386755083 creator A5072743201 @default.
• W4386755083 date "2023-09-14" @default.
• W4386755083 modified "2023-09-26" @default.
• W4386755083 title "Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition" @default.
• W4386755083 cites W1923415053 @default.
• W4386755083 cites W2054077136 @default.
• W4386755083 cites W2066466450 @default.
• W4386755083 cites W2096246254 @default.
• W4386755083 cites W2097854437 @default.
• W4386755083 cites W2101863341 @default.
• W4386755083 cites W2137747726 @default.
• W4386755083 cites W2152623033 @default.
• W4386755083 cites W2260643844 @default.
• W4386755083 cites W2281540926 @default.
• W4386755083 cites W2338854794 @default.
• W4386755083 cites W2350361926 @default.
• W4386755083 cites W2471768068 @default.
• W4386755083 cites W2561678715 @default.
• W4386755083 cites W2622276831 @default.
• W4386755083 cites W2625644909 @default.
• W4386755083 cites W2786491861 @default.
• W4386755083 cites W2790375504 @default.
• W4386755083 cites W2891397155 @default.
• W4386755083 cites W2915918622 @default.
• W4386755083 cites W2969393452 @default.
• W4386755083 cites W3000776376 @default.
• W4386755083 cites W3012307018 @default.
• W4386755083 cites W3019384206 @default.
• W4386755083 cites W3027492459 @default.
• W4386755083 cites W3121216800 @default.
• W4386755083 cites W3152524207 @default.
• W4386755083 cites W3189369858 @default.
• W4386755083 cites W3197355720 @default.
• W4386755083 cites W3197818736 @default.
• W4386755083 cites W3216683313 @default.
• W4386755083 cites W4280542721 @default.
• W4386755083 cites W4309376068 @default.
• W4386755083 cites W4311312154 @default.
• W4386755083 cites W4318274758 @default.
• W4386755083 cites W4367056731 @default.
• W4386755083 doi "https://doi.org/10.33590/emj/10308910" @default.
• W4386755083 hasPublicationYear "2023" @default.
• W4386755083 type Work @default.
• W4386755083 citedByCount "0" @default.
• W4386755083 crossrefType "journal-article" @default.
• W4386755083 hasAuthorship W4386755083A5072743201 @default.
• W4386755083 hasBestOaLocation W43867550831 @default.
• W4386755083 hasConcept C126322002 @default.
• W4386755083 hasConcept C177713679 @default.
• W4386755083 hasConcept C2776301958 @default.
• W4386755083 hasConcept C2777292125 @default.
• W4386755083 hasConcept C2778205648 @default.
• W4386755083 hasConcept C2778661090 @default.
• W4386755083 hasConcept C2779161974 @default.
• W4386755083 hasConcept C2780638905 @default.
• W4386755083 hasConcept C2780868729 @default.
• W4386755083 hasConcept C2781413609 @default.
• W4386755083 hasConcept C2908647359 @default.
• W4386755083 hasConcept C3017811039 @default.
• W4386755083 hasConcept C535046627 @default.
• W4386755083 hasConcept C57002609 @default.
• W4386755083 hasConcept C71924100 @default.
• W4386755083 hasConcept C89560881 @default.
• W4386755083 hasConcept C99454951 @default.
• W4386755083 hasConceptScore W4386755083C126322002 @default.
• W4386755083 hasConceptScore W4386755083C177713679 @default.
• W4386755083 hasConceptScore W4386755083C2776301958 @default.
• W4386755083 hasConceptScore W4386755083C2777292125 @default.
• W4386755083 hasConceptScore W4386755083C2778205648 @default.
• W4386755083 hasConceptScore W4386755083C2778661090 @default.
• W4386755083 hasConceptScore W4386755083C2779161974 @default.
• W4386755083 hasConceptScore W4386755083C2780638905 @default.
• W4386755083 hasConceptScore W4386755083C2780868729 @default.
• W4386755083 hasConceptScore W4386755083C2781413609 @default.
• W4386755083 hasConceptScore W4386755083C2908647359 @default.
• W4386755083 hasConceptScore W4386755083C3017811039 @default.
• W4386755083 hasConceptScore W4386755083C535046627 @default.
• W4386755083 hasConceptScore W4386755083C57002609 @default.
• W4386755083 hasConceptScore W4386755083C71924100 @default.
• W4386755083 hasConceptScore W4386755083C89560881 @default.
• W4386755083 hasConceptScore W4386755083C99454951 @default.
• W4386755083 hasLocation W43867550831 @default.
• W4386755083 hasOpenAccess W4386755083 @default.
• W4386755083 hasPrimaryLocation W43867550831 @default.
• W4386755083 hasRelatedWork W2060633440 @default.
• W4386755083 hasRelatedWork W2181601210 @default.
• W4386755083 hasRelatedWork W2399439482 @default.
• W4386755083 hasRelatedWork W2509901103 @default.
• W4386755083 hasRelatedWork W2555550897 @default.
• W4386755083 hasRelatedWork W2886912737 @default.
• W4386755083 hasRelatedWork W2895255751 @default.
• W4386755083 hasRelatedWork W2990629389 @default.
• W4386755083 hasRelatedWork W3028955534 @default.
• W4386755083 hasRelatedWork W4224288855 @default.
• W4386755083 isParatext "false" @default.
• W4386755083 isRetracted "false" @default.

• next